Who
Richard K. Prins
Director
Company insider
Files Form 4 as: Director, Amphastar Pharmaceuticals; Director, IGC Pharma.
In numbers
- Trades disclosed
- 549
- Buys
- 3
- Sells
- 49
- Bought
- $40K
- Sold
- $8.2M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 13 May 2009
- Last trade
- 11 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Aug 2026filed 12 Aug 2026 | AMPH Amphastar PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $162K7,973 at $20.30 | filing |
| 11 Aug 2026filed 12 Aug 2026 | AMPH Amphastar PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $162K7,973 at $20.30 | filing |
| 1 Jun 2026filed 3 Jun 2026 | AMPH Amphastar PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —8,143 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | AMPH Amphastar Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —17,365 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | AMPH Amphastar Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —17,365 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | AMPH Amphastar PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —8,143 at $0.00 | filing |
| 1 Apr 2026filed 6 Apr 2026 | IGC IGC PharmaBiotechnology | SEC FORM 4 Code M | —100,000 at $0.00 | filing |
| 1 Apr 2026filed 6 Apr 2026 | IGC IGC PharmaBiotechnology | SEC FORM 4 Code M | —70,000 at $0.00 | filing |
| 1 Apr 2026filed 6 Apr 2026 | IGC IGC Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —100,000 at $0.00 | filing |
| 1 Apr 2026filed 6 Apr 2026 | IGC IGC Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —100,000 at $0.00 | filing |
| 1 Apr 2026filed 6 Apr 2026 | IGC IGC Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —70,000 at $0.00 | filing |
| 1 Apr 2026filed 6 Apr 2026 | IGC IGC Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —70,000 at $0.00 | filing |
| 1 Apr 2026filed 6 Apr 2026 | IGC IGC PharmaBiotechnology | SEC FORM 4 Code M | —100,000 at $0.00 | filing |
| 1 Apr 2026filed 6 Apr 2026 | IGC IGC PharmaBiotechnology | SEC FORM 4 Code M | —70,000 at $0.00 | filing |
| 19 Jan 2026filed 20 Jan 2026 | IGC IGC PharmaBiotechnology | SEC FORM 4 Code M | —100,000 at $0.00 | filing |
| 19 Jan 2026filed 20 Jan 2026 | IGC IGC Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —100,000 at $0.00 | filing |
| 19 Jan 2026filed 20 Jan 2026 | IGC IGC Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —100,000 at $0.00 | filing |
| 19 Jan 2026filed 20 Jan 2026 | IGC IGC PharmaBiotechnology | SEC FORM 4 Code M | —100,000 at $0.00 | filing |
| 25 Nov 2025filed 25 Nov 2025 | AMPH Amphastar Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,179 at $0.00 | filing |
| 25 Nov 2025filed 25 Nov 2025 | AMPH Amphastar PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $70K4,179 at $16.69 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Cut to Buy at Wall Street ZenAMPH · dailypolitical.com · 25 Oct 2026Analyzing Amphastar Pharmaceuticals (NASDAQ:AMPH) and ImmuCell (NASDAQ:ICCC)AMPH · dailypolitical.com · 24 Oct 2026Comparing Amphastar Pharmaceuticals (NASDAQ:AMPH) & Enanta Pharmaceuticals (NASDAQ:ENTA)AMPH · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name Richard K. Prins; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.